Identification of biomarkers for colorectal cancer through proteomics-based approaches

References

• Jass JR, Morson BC. Reporting colorectal cancer. J. Clin. Pathol.40, 1016–1023 (1987).
   PubMed Web of Science ®Google Scholar
• Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett.249, 87–96 (2007).
   PubMed Web of Science ®Google Scholar
• Simon J. Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved. N. Engl. J. Med.338, 1151–1152 (1998).
   PubMed Web of Science ®Google Scholar
• Lieberman D. Clinical practice. Screening for colorectal cancer. N. Engl. J. Med.361, 1179–1187 (2009).
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J. Clin.59, 366–378 (2009).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Digital PCR. Proc. Natl Acad. Sci. USA96, 9236–9241 (1999).
   PubMed Web of Science ®Google Scholar
• Melotte V, Lentjes M, van den Bosch S et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl. Cancer Inst.101, 916–927 (2009).
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Tanaka N, Cullings HM et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl. Cancer Inst.101, 1244–1258 (2009).
   PubMedGoogle Scholar
• Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol. (Oxf.)18, 15–24 (2009).
   PubMed Web of Science ®Google Scholar
• Duffy MJ, van Dalen A, Haglund C et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer43, 1348–1360 (2007).
   PubMed Web of Science ®Google Scholar
• Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn.8, 277–288 (2008).
   PubMed Web of Science ®Google Scholar
• Sagynaliev E, Steinert R, Nestler G, Lippert H, Knoch M, Reymond MA. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics5, 3066–3078 (2005).
   PubMed Web of Science ®Google Scholar
• Reymond MA, Steinert R, Kahne T, Sagynaliev E, Allal AS, Lippert H. Expression and functional proteomics studies in colorectal cancer. Pathol. Res. Pract.200, 119–127 (2004).
   PubMed Web of Science ®Google Scholar
• Barderas R, Babel I, Casal JI. Colorectal cancer proteomics molecular characterization and biomarker discovery. Proteomics Clin. Appl.4, 159–178 (2010).
   PubMed Web of Science ®Google Scholar
• O’Farrell P. The pre-omics era: the early days of two-dimensional gels. Proteomics8(23–24), 4842–4852 (2008).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359(9306), 572–577 (2002).
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma proteomics. Chem. Rev.107, 3601–3620 (2007).
   PubMed Web of Science ®Google Scholar
• Mehta AI, Ross S, Lowenthal MS et al. Biomarker amplification by serum carrier protein binding. Dis. Markers19, 1–10 (2003).
   PubMed Web of Science ®Google Scholar
• Seam N, Gonzales DA, Kern SJ, Hortin GL, Hoehn GT, Suffredini AF. Quality control of serum albumin, depletion for proteomic analysis. Clin. Chem.53, 1915–1920 (2007).
   PubMed Web of Science ®Google Scholar
• Hu LH, Ye ML, Zou HF. Recent advances in mass spectrometry-based peptidome analysis. Expert Rev. Proteomics6, 433–447 (2009).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer6, 961–967 (2006).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Martorella AJ, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics5, 1840–1852 (2006).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Temps P. A sequence-specific exopeptidase activity test (SSEAT) for ‘functional’ biomarker discovery. Mol. Cell. Proteomics7, 509–518 (2008).
   PubMed Web of Science ®Google Scholar
• Peccerella T, Lukan N, Hofheinz R et al. Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Clin. Chem.56, 272–280 (2010).
   PubMed Web of Science ®Google Scholar
• Dekker LJ, Burgers PC, Charif H et al. Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics10(12), 2348–2358 (2010).
   PubMed Web of Science ®Google Scholar
• Check E. Proteomics and cancer – running before we can walk? Nature429, 496–497 (2004).
   PubMed Web of Science ®Google Scholar
• Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst.97, 307–309 (2005).
   PubMed Web of Science ®Google Scholar
• Gast MC, van Gils CH, Wessels LFA et al. Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Clin. Chem. Lab. Med.47, 694–705 (2009).
   PubMed Web of Science ®Google Scholar
• Findeisen P, Neumaier M. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin. Chem. Lab. Med.47, 666–684 (2009).
   PubMed Web of Science ®Google Scholar
• Wright GL. 2-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann. Clin. Lab. Sci.4, 281–293 (1974).
   PubMed Web of Science ®Google Scholar
• de Noo ME, Mertens BJA, Ozalp A et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer42, 1068–1076 (2006).
   PubMed Web of Science ®Google Scholar
• de Noo ME, Tollenaar R, Deelder AM, Bouwman LH. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J. Gastroenterol.12, 6594–6601 (2006).
   PubMed Web of Science ®Google Scholar
• Tuck MK, Chan DW, Chia D et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res.8, 113–117 (2009).
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng ZD et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem.54, 53–60 (2008).
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem.54, 44–52 (2008).
   PubMed Web of Science ®Google Scholar
• Ward DG, Suggett N, Cheng Y et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer94, 1898–1905 (2006).
   PubMed Web of Science ®Google Scholar
• Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res.10, 8380–8385 (2004).
   PubMed Web of Science ®Google Scholar
• Yu J, Chen Y, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol.10, 3127–3131 (2004).
   PubMed Web of Science ®Google Scholar
• Liu X, Shen J, Li Z, Yan L, Gu J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest.24, 747–753 (2006).
   PubMed Web of Science ®Google Scholar
• Ward DG, Nyangoma S, Joy H et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci.6, 19 (2008).
   PubMedGoogle Scholar
• Ward DG, Roberts K, Brookes MJ et al. Increased hepcidin expression in colorectal carcinogenesis. World J. Gastroenterol.14, 1339–1345 (2008).
   PubMed Web of Science ®Google Scholar
• Kemna E, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica93, 90–97 (2008).
   PubMed Web of Science ®Google Scholar
• Schlosser G, Pocsfalvi G, Huszar E, Malorni A, Hudecz F. MALDI-TOF mass spectrometry of a combinatorial peptide library: effect of matrix composition on signal suppression. J. Mass Spectrom.40, 1590–1594 (2005).
   PubMed Web of Science ®Google Scholar
• Szajli E, Feher T, Medzihradszky KF. Investigating the quantitative nature of MALDI-TOF MS. Mol. Cell. Proteomics7, 2410–2418 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Q, Shen J, Li ZF et al. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer9, 287 (2009).
   PubMed Web of Science ®Google Scholar
• Swinkels DW, Girelli D, Laarakkers C et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PloS ONE3(7), e2706 (2008).
   PubMed Web of Science ®Google Scholar
• Quaresima B, Crugliano T, Gaspari M et al. A proteomics approach to identify changes in protein profiles in serum of Familial adenomatous polyposis patients. Cancer Lett.272, 40–52 (2008).
   PubMed Web of Science ®Google Scholar
• Hung KE, Kho AT, Sarracino D et al. Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J. Proteome Res.5, 1866–1878 (2006).
   PubMed Web of Science ®Google Scholar
• Kocer B, McKolanis J, Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol.6, 4 (2006).
   PubMed Web of Science ®Google Scholar
• Silk AW, Schoen RE, Potter DM, Finn OJ. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol. Immunol.47, 52–56 (2009).
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Byrd JC, Tessler D et al. A circulating ligand for galectin-3 glycoprotein elevated in individual is a haptoglobin-related with colon cancer. Gastroenterology127, 741–748 (2004).
   PubMed Web of Science ®Google Scholar
• Arredondo M, Kloosterman J, Nunez S et al. Heme iron uptake by Caco-2 cells is a saturable, temperature sensitive and modulated by extracellular pH and potassium. Biological Trace Element Res.125, 109–119 (2008).
   PubMed Web of Science ®Google Scholar
• Peng JY, Zhang QF, Ma YL et al. A rat-to-human search for proteomic alterations reveals transgelin as a biomarker relevant to colorectal carcinogenesis and liver metastasis. Electrophoresis30, 2976–2987 (2009).
   PubMed Web of Science ®Google Scholar
• Xing PX, Young GP, Ho D, Sinatra MA, Hoj PB, McKenzie IF. A new approach to fecal occult blood testing based on the detection of haptoglobin. Cancer78, 48–56 (1996).
   PubMed Web of Science ®Google Scholar
• Reuschenbach M, Kloor M, Morak M et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Familial Cancer9, 173–179 (2010).
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Schaeps RM, Swinkels DW. Immunoproteomics: from biomarker discovery to diagnostic applications. Proteomics Clin. Appl.2, 167–180 (2008).
   PubMed Web of Science ®Google Scholar
• He YJ, Mou ZR, Li WL et al. Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis. Int. J. Colorectal Dis.24, 1271–1279 (2009).
   PubMed Web of Science ®Google Scholar
• Collart FR, Chubb CB, Mirkin BL, Huberman E. I Increased inosine-5´-phosphate dehydrogenase gene-expression in solid tumor-tissues and tumor-cell lines. Cancer Res.52, 5826–5828 (1992).
   PubMed Web of Science ®Google Scholar
• Ran YL, Hu H, Zhou Z et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin. Cancer Res.14, 2696–2700 (2008).
   PubMed Web of Science ®Google Scholar
• Babel I, Barderas R, Diaz-Uriarte R, Martinez-Torrecuadrada JL, Sanchez-Carbayo M, Casal JI. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol. Cell. Proteomics8, 2382–2395 (2009).
   PubMed Web of Science ®Google Scholar
• Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr. Opin. Immunol.7, 812–818 (1995).
   PubMed Web of Science ®Google Scholar
• Hausen HZ. Streptococcus bovis: causal or incidental involvement in cancer of the colon? Int. J. Cancer119, XI–XII (2006).
   PubMedGoogle Scholar
• Tjalsma H, Scholler-Guinard M, Lasonder E, Ruers TJ, Willems HL, Swinkels DW. Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int. J. Cancer119, 2127–2135 (2006).
   PubMed Web of Science ®Google Scholar
• Boleij A, Roelofs R, Schaeps RM et al. Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients. Cancer116(17), 4014–4022 (2010).
   PubMed Web of Science ®Google Scholar
• Abdulamir AS, Hafidh RR, Mahdi LK, Al-Jeboori T, Abubaker F. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer9, 403 (2009).
   PubMed Web of Science ®Google Scholar
• Ma YL, Peng JY, Liu WJ et al. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol. Cell. Proteomics8, 1878–1890 (2009).
   PubMed Web of Science ®Google Scholar
• Bendtsen JD, Jensen LJ, Blom N, von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel.17, 349–356 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang YB, Ye YJ, Shen DH et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci.101, 523–529 (2010).
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Pluk W, van den Heuvel LP, Peters WH, Roelofs R, Swinkels DW. Proteomic inventory of ‘anchorless’ proteins on the colon adenocarcinoma cell surface. Biochim. Biophys. Acta Proteins Proteomics1764, 1607–1617 (2006).
   PubMed Web of Science ®Google Scholar
• Xing XM, Lai MD, Wang YH, Xu EP, Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin. Chim. Acta364, 308–315 (2006).
   PubMed Web of Science ®Google Scholar
• Roessler M, Rollinger W, Palme S et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res.11, 6550–6557 (2005).
   PubMed Web of Science ®Google Scholar
• Roessler M, Rollinger W, Mantovani-Endl L et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics5, 2092–2101 (2006).
   PubMed Web of Science ®Google Scholar
• Kim H, Kang HJ, You KT et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics6, 3466–3476 (2006).
   PubMed Web of Science ®Google Scholar
• Chen WS, Chang HY, Li CP, Liu JM, Huang TS. Tumor β-1,4-galactosyltransferase IV overexpression is closely associated with colorectal cancer metastasis and poor prognosis. Clin. Cancer Res.11, 8615–8622 (2005).
   PubMed Web of Science ®Google Scholar
• Larriba MJ, Casado-Vela J, Pendas-Franco N et al. Novel Snail1 target proteins in human colon cancer identified by proteomic analysis. PloS ONE5, E10221 (2010).
   PubMed Web of Science ®Google Scholar
• Renert AF, Leprince P, Dieu M et al. The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. J. Proteome Res.8, 4810–4822 (2009).
   PubMed Web of Science ®Google Scholar
• Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol.340, 783–795 (2004).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kang HJ, Lee H et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res.8, 1368–1379 (2009).
   PubMed Web of Science ®Google Scholar
• Lambert O, Cavusoglu N, Gallay J et al. Novel organization and properties of annexin 2-membrane complexes. J. Biol. Chem.279, 10872–10882 (2004).
   PubMed Web of Science ®Google Scholar
• Melle C, Ernst G, Schimmel B, Bleul A, von Eggeling F. Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca2+-binding proteins S100A6 and S100A11. PloS ONE3, E3767 (2008).
   PubMed Web of Science ®Google Scholar
• Melle C, Ernst G, Schimmel B et al. Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology129, 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res.62, 2437–2442 (2002).
   PubMed Web of Science ®Google Scholar
• Konety BR, Nguyen TS, Brenes G et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol.164, 634–639 (2000).
   PubMed Web of Science ®Google Scholar
• Miller TE, Beausang LA, Winchell LF, Lidgard GP. Detection of nuclear matrix proteins in serum from cancer-patients. Cancer Res.52, 422–427 (1992).
   PubMed Web of Science ®Google Scholar
• Walgenbach-Brunagel G, Burger B, Leman ES et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J. Cell. Biochem.104, 286–294 (2008).
   PubMed Web of Science ®Google Scholar
• Caldwell RL, Caprioli RM. Tissue profiling by mass spectrometry – a review of methodology and applications. Mol. Cell. Proteomics4, 394–401 (2005).
   PubMed Web of Science ®Google Scholar
• Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J. Proteome Res.5, 2889–2900 (2006).
   PubMed Web of Science ®Google Scholar
• Mazzanti R, Solazzo M, Fantappie O et al. Differential expression proteomics of human colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol.290, G1329–G1338 (2006).
   PubMed Web of Science ®Google Scholar
• Pei HP, Zhu H, Zeng S et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res.6, 2495–2501 (2007).
   PubMed Web of Science ®Google Scholar
• Hanash S. It takes a village to develop biomarkers. J. Proteome Res.6, 3362 (2007).
   PubMed Web of Science ®Google Scholar
• Ruginis T, Taglia L, Matusiak D, Lee BS, Benya RV. Consequence of gastrin-releasing peptide receptor activation in a human colon cancer cell line: a proteomic approach. J. Proteome Res.5, 1460–1468 (2006).
   PubMed Web of Science ®Google Scholar
• Dippold W, Wittig B, Schwaeble W, Mayet W, Zumbuschenfelde KH. Expression of intercellular-adhesion molecule-1 (Icam-1, Cd54) in colonic epithelial-cells. Gut34, 1593–1597 (1993).
   PubMed Web of Science ®Google Scholar
• Gaedtke L, Thoenes L, Culmsee C, Mayer B, Wagner E. Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. J. Proteome Res.6, 4111–4118 (2007).
   PubMed Web of Science ®Google Scholar
• Nam MJ, Kee MK, Kuick R, Hanash SM. Identification of defensin a 6 as a potential biomarker in colon adenocarcinoma. J. Biol. Chem.280, 8260–8265 (2005).
   PubMed Web of Science ®Google Scholar
• Lawlor K, Nazarlan A, Lacomis L, Tempst P, Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res.8, 1489–1503 (2009).
   PubMed Web of Science ®Google Scholar
• Shi HJ, Stubbs R, Hood K. Characterization of de novo synthesized proteins released from human colorectal tumour explants. Electrophoresis30, 2442–2453 (2009).
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen HC, Chen SJ et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics8, 316–332 (2008).
   PubMed Web of Science ®Google Scholar
• Llanos S, Efeyan A, Monsech J, Dominguez O, Serrano M. A high-throughput loss-of-function screening identifies novel p53 regulators. Cell Cycle5, 1880–1885 (2006).
   PubMed Web of Science ®Google Scholar
• Volmer MW, Stuhler K, Zapatka M et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics5, 2587–2601 (2005).
   PubMed Web of Science ®Google Scholar
• Rangiah K, Tippornwong M, Sangar V et al. Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J. Proteome Res.8, 5153–5164 (2009).
   PubMed Web of Science ®Google Scholar
• Yang X, Lazar IM. MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer9, 96 (2009).
   PubMedGoogle Scholar
• Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem.56(2), 212–222 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin P, Qiu SM et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int. J. Oncol.30, 1137–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin. Cancer Res.6, 505–511 (2000).
   PubMed Web of Science ®Google Scholar
• Verberkmoes NC, Russell AL, Shah M et al. Shotgun metaproteomics of the human distal gut microbiota. ISME J.3, 179–189 (2009).
   PubMed Web of Science ®Google Scholar
• Ang C, Rothacker J, Patsiouras H, Burgess A, Nice E. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. J. Chromatogr. A1217, 3330–3340 (2010).
   PubMed Web of Science ®Google Scholar
• Karl J, Wild N, Tacke M et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol.6, 1122–1128 (2008).
   PubMed Web of Science ®Google Scholar
• Kaiser J. Cancer – first pass at cancer genome reveals complex landscape. Science313, 1370 (2006).
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science314, 268–274 (2006).
   PubMed Web of Science ®Google Scholar
• Kilpelainen TP, Tammela TL, Maattanen L et al. False-positive screening results in the Finnish prostate cancer screening trial. Br. J. Cancer102, 469–474 (2010).
   PubMed Web of Science ®Google Scholar
• Gigerenzer G. Making sense of health statistics. Bull. World Health Organ.87, 567 (2009).
   PubMed Web of Science ®Google Scholar
• Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J. Natl. Cancer Inst.101, 1216–1220 (2009).
   PubMed Web of Science ®Google Scholar